Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Kazia Therapeutics has completed the recruitment of patients into Part B of its phase I clinical study of Cantrixil in ovarian cancer
  • Cantrixil is a first-in-class development candidate which targets the entire spectrum of cancerous and tumour-initiating cells
  • A maximum tolerated dosage of 5mg/kg was achieved in Part A of the study

Australian oncology company Kazia Therapeutics has completed the recruitment of patients for Part B of its phase I clinical study of Cantrixil in ovarian cancer.

Cantrixil is a first-in-class development candidate which targets the entire spectrum of cancer cells and also tumour-initiating cells that are thought to cause cancer recurrence.

It is currently being developed for the treatment of ovarian cancer and is being trialled at hospitals in both Australia and the United States.

Approximately 240,000 women are diagnosed with ovarian cancer each year worldwide and it’s the eighth most common cause of cancer death in women.

Typical treatments include surgery, chemotherapy and radiotherapy however, the five-year survival rate remains low at 45 per cent.

Part A of the study collected data from an initial 14 patients who received increasing doses of Cantrixil to determine both the safety and tolerability.

A maximum tolerated dosage of 5mg/kg was achieved and this data was reported to the American Association of Cancer Research conference on April 1, 2019.

The data showed that of the nine patients who were evaluated five of them, 56 per cent, achieved a best observed respire of stable disease after two cycles of Cantrixil monotherapy.

However, one of these patients was administered Cantrixil with chemotherapy and only received a partial response.

Final data from these nine patients have been selected for presentation at the European Society of Medical Oncology Annual Meeting in Barcelona from September 27 – October 1, 2020.

Part B was designed to enlist 12 patients with each receiving Cantrixil at a dose of 5mg/kg, and also seek preliminary signals of potential efficacy for the drug.

Initial data from Part B is expected in the fourth quarter of 2019 with final completion in 2020.

“Part B of the Cantrixil study has recruited well and we are now following patients through to completion of their treatment,” CEO of Kazia Dr James Garner said.

“The first part of the study has shown some very promising signals, and the data from Part B will significantly enhance our understanding of the drug.”

KZA by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.